A pair of U.S. lawmakers is urging the Federal Commerce Fee to research the dad or mum corporations of two giant pharmacy profit managers over issues that new enterprise items may unfairly steer sufferers towards higher-cost medicines.
The trouble comes after CVS Well being and Cigna — which personal CVS Caremark and Specific Scripts, respectively — launched subsidiaries which might be putting “co-manufacturing” offers with corporations that make biologic medicines and lower-cost variations generally known as biosimilars. These new enterprise items have since used these offers as springboards to market the drugs to well being plans.
In actuality, the preparations truly resemble private-label distribution, however the lawmakers fear these agreements might trigger customers to pay increased costs. How so? The enterprise items at the moment are competing with pharmaceutical corporations for placement on formularies — the record of medicines lined by medical health insurance — and the lawmakers argue there are incentives to favor the medicine they’re supplying.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
